share_log

EyePoint Pharmaceuticals | 8-K: EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals | 8-K: EyePoint Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Developments

EyePoint Pharmaceuticals | 8-K:EyePoint Pharmicals公佈2024年第二季度財務業績並重點介紹最近的公司發展
美股SEC公告 ·  08/07 19:01

牛牛AI助理已提取核心訊息

EyePoint Pharmaceuticals, Inc. reported its financial results for the second quarter ended June 30, 2024, on August 7, 2024. The company announced a net revenue of $9.5 million for the quarter, a slight increase from $9.1 million in the same period the previous year. Net product revenue, however, decreased to $1.1 million from $5.3 million in Q2 2023, following the out-license of the YUTIQ franchise. Royalties and collaborations revenue rose to $8.4 million, up from $3.8 million, due to the recognition of deferred revenue from the YUTIQ license. Operating expenses increased to $44.0 million, driven by research and development costs, particularly for the DURAVYU clinical trials. The company reported a net loss of $30.8 million, or ($0.58) per share, compared to a net loss of $22.9 million, or ($0.61) per share, in the prior year. Cash...Show More
EyePoint Pharmaceuticals, Inc. reported its financial results for the second quarter ended June 30, 2024, on August 7, 2024. The company announced a net revenue of $9.5 million for the quarter, a slight increase from $9.1 million in the same period the previous year. Net product revenue, however, decreased to $1.1 million from $5.3 million in Q2 2023, following the out-license of the YUTIQ franchise. Royalties and collaborations revenue rose to $8.4 million, up from $3.8 million, due to the recognition of deferred revenue from the YUTIQ license. Operating expenses increased to $44.0 million, driven by research and development costs, particularly for the DURAVYU clinical trials. The company reported a net loss of $30.8 million, or ($0.58) per share, compared to a net loss of $22.9 million, or ($0.61) per share, in the prior year. Cash and investments totaled $280.2 million, providing a cash runway through anticipated Phase 3 wet AMD topline data for DURAVYU in 2026. EyePoint Pharmaceuticals also highlighted progress in its clinical trials, including the Phase 3 LUGANO trial for DURAVYU in wet AMD, set to begin patient dosing in 2024, and the fully enrolled Phase 2 VERONA trial in DME, with topline data expected in Q1 2025.
EyePoint Pharmaceuticals公司於2024年8月7日公佈了截至2024年6月30日第二季度的財務業績報告。該公司公佈該季度淨收入爲950萬美元,略微高於去年同期的910萬美元。然而,淨產品收入從2023年Q2的530萬美元下降至110萬美元,這是由於YUTIQ特許經營權的出讓。版稅和合作收入上升至840萬美元,高於380萬美元,這是由於YUTIQ許可證的遞延收入認定。營業費用增加至4400萬美元,由研發成本驅動,特別是爲DURAVYU臨床試驗而產生的成本。該公司報告淨虧損3080萬美元,每股虧損(0.58)美元,相比之下,去年同期淨虧損2290萬美元,每股虧損(0.61)美...展開全部
EyePoint Pharmaceuticals公司於2024年8月7日公佈了截至2024年6月30日第二季度的財務業績報告。該公司公佈該季度淨收入爲950萬美元,略微高於去年同期的910萬美元。然而,淨產品收入從2023年Q2的530萬美元下降至110萬美元,這是由於YUTIQ特許經營權的出讓。版稅和合作收入上升至840萬美元,高於380萬美元,這是由於YUTIQ許可證的遞延收入認定。營業費用增加至4400萬美元,由研發成本驅動,特別是爲DURAVYU臨床試驗而產生的成本。該公司報告淨虧損3080萬美元,每股虧損(0.58)美元,相比之下,去年同期淨虧損2290萬美元,每股虧損(0.61)美元。現金和投資總額爲28020萬美元,爲預計於2026年DURAVYU溼型AMD第三階段頂線數據提供了現金餘地。EyePoint Pharmaceuticals還強調了其臨床試驗的進展情況,其中包括DURAVYU治療溼型AMD的第3期LUGANO試驗,在2024年開始患者劑量配置,並且目前已招募完成的DME第2期VERONA試驗,其頂線數據預計在2025年第1季度公佈。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。